Key Highlights:
- Leap Therapeutics rebrands itself as Cypherpunk Technologies.
- The company has purchased 203,775.27 ZEC.
- Cypherpunk’s stock ticker will change to CYPH on Nasdaq.
Nasdaq-listed Leap Therapeutics, Inc., a biotech company, has redefined its corporate identity and financial strategy to embrace digital assets. Leap Therapeutics has announced its rebranding to Cypherpunk technologies Inc., and it also revealed that it is transforming into a vault company that will be centred on cryptocurrency treasury management. Alongside maintaining its ongoing biotech research and development, Leap is allocating a significant portion of its capital into crypto assets-specifically, Zcash (ZEC).
纳斯达克上市生物科技公司 Leap Therapeutics 宣布更名为 Cypherpunk Technologies Inc，并正式转型为以数字资产为核心的金库公司。公司以平均每枚 245 美元的价格购入 203,775.27 枚 ZEC，资金来自由 Winklevoss Capital 领投的 5,888 万美元私募融资。Cypherpunk…
— 吴说区块链 (@wublockchain12) November 12, 2025
Cypherpunk Technologies has already acquired 203,775.27 ZEC at an average purchase price of $245.34 per coin. Leap has deployed $50 million from a $58.88 million private financing round led by Winklevoss Capital.
The company is now planning a Nasdaq ticker change to CYPH, effective from November 13, 2025. This shows that the company is focused on developing medical breakthroughs while also increasing shareholder value by strategically adding crypto assets.
It has been observed that many of the biotech companies have started using digital assets as their secondary source of finance. As we all know, research requires a huge amount of monetary backing and it is very difficult to raise funds for the same. That’s when digital assets come into the picture. These biotech companies invest in crypto (such as Bitcoin, Ethereum and privacy coins such as Zcash’s ZEC) and as the price of the crypto rises, the companies enjoys the profit as it helps them carry out their research.
Financial and Strategic Implications for Biotech Investors
More and more companies now see cryptocurrencies not just as a risky investment, but they look at it as a smart way to diversify their treasury. When these companies invest in crypto, it can provide them protection against inflation and it also provides a way for them to raise money for their research projects.
The only concern that is usually raised when it comes to crypto treasury is that the crypto market is highly volatile. Companies have to be prepared for the good days and the bad days as well. They need to have a plan and a protocol when things go south.
Cypherpunk Technologies, for example, says it will continue focusing on its main biotech goal of developing cancer treatments. The main reason why the company is investing in crypto because it wants something that can help Leap Therapeutics survive on its own in the long-term.
Other Biotech Firm Embracing Crypto Treasury Strategies
Leap/Cypherpunk is not the first one to adopt crypto treasury strategy for funding purposes. There are various biotech companies that have incorporated digital assets into their treasury strategies. A few of them have been listed below:
Hoth Therapeutics (NASDAQ: HOTH): A clinical-stage biopharma developing treatments for skin, neurological and inflammatory conditions, has allocated up to $1 million in Bitcoin to its treasury starting in late 2024. For a research-focused biotech, this was a bold step, showing that even drug-development companies now see crypto as an inflation hedge and a way to increase cash reserves.
Propanc Biopharma (NASDAQ: PPCB): A company that works on cancer-therapy platform that stops the growth of the tumour and prevents metastasis. It worked on its intellectual property with a treasury diversification plan in 2025. The company plans to acquire $100 million worth of Ethereum in the next 12 months. The main goal is to use the price appreciation and liquidity to support the research without diluting the shares.
Sonnet BioTherapeutics (NASDAQ: SONN): An oncology company that develops targeted cytokine-based tumour therapies announced plans to shift toward a crypto-treasury model by accumulating tokens such as HYPE Crypto. Its stock jumped based on the expected value to these holdings, showing investor appetite for biotech firms using digital assets alongside traditional research operations.
Also Read: Aster Token Mission Ignites: Will It Blast Past $10?
